#	Pagina
attuale pagina	/open-h2020/projects/200846/index.html
-1	/open-h2020/projects/226330/index.html

Opendata, web and dolomites

SPRAYNERGY

Translational synergistic growth factor microenvironments for bone regeneration

Total Cost €

EC-Contrib. €

Partnership

Views

SPRAYNERGY project word cloud

Explore the words cloud of the SPRAYNERGY project. It provides you a very rough idea of what is the project "SPRAYNERGY" about.

translational cell tissue direct patent complications nanometric fn clinic degradable size defects bone meek region lower taragenyx construct versatile clinical grant coated protein model defect critical morphogenesis sequester induce murine signalling stages regeneration rhbmp2 planning hurdle safer route shown morphogenetic safe layer domain surgeon acrylate overcome appraisal combination licensed fibronectin filed doses recombinant encountered standpoint gfs integrin synergy vascularisation material union gf poly commercial spray pea commercialisation polymer simultaneous powerful ethyl later scaling erc bulk engineering stem presentation localised co dr functional regenerate sme patients fabricate ltd binding teamed human receptors competitive serious enhances engineered rhbmp integrins vivo differentiation

Project "SPRAYNERGY" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITY OF GLASGOW Organization address address: UNIVERSITY AVENUE city: GLASGOW postcode: G12 8QQ website: www.gla.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	148˙783 €
EC max contribution	148˙783 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2015-PoC
Funding Scheme	ERC-POC
Starting year	2016
Duration (year-month-day)	from 2016-06-01 to 2017-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITY OF GLASGOW UNIVERSITY OF GLASGOW Organization address address: UNIVERSITY AVENUE city: GLASGOW postcode: G12 8QQ website: www.gla.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (GLASGOW)	coordinator	148˙783.00

Map

Project objective

We propose a robust polymer-based system that allows a safer delivery of recombinant human bone morphogenetic protein-2 (rhBMP2) for bone tissue engineering. We have teamed up with a surgeon (Dr. Meek) and an SME (Taragenyx Ltd.) in the planning stages, for the appraisal of the proposal from a translational standpoint. Later, Taragenyx will also be involved with scaling-up and commercialisation. We filed a patent covering the technology, and licensed Taragenyx its exploitation. rhBMP2 is a powerful human growth factor (GF) essential in tissue morphogenesis and used to promote bone growth in clinical applications. Current clinical delivery has encountered serious complications associated with the high doses used. We have developed a system that allows the effective presentation of GFs in combination with the integrin binding domain of fibronectin (FN), promoting simultaneous and co-localised signalling between GF receptors and integrins. We have shown the ability of Poly(ethyl acrylate) PEA to organise FN and sequester rhBMP2 in synergy with the integrin binding region to direct stem cell differentiation. This technology enhances bone regeneration and vascularisation with lower rhBMP-2 doses. With this understanding we have engineered a system to regenerate a bone critical size defect in a murine model. Results were comparable to the higher doses used in the clinic, which makes the system safe, effective and more competitive than current commercial products. PEA is however a non-degradable material, a major hurdle to be overcome for many potential applications. We will fabricate a degradable construct spray-coated with a nanometric layer of this functional material to induce and direct bone growth – as already shown for the bulk polymer in our ERC Grant, and investigate in vivo the engineered systems. Overall, we will develop a safe and versatile bone system for clinical use in patients with non-union bone defects, and set a route towards commercialisation.

Publications

List of publications.
year	authors and title	journal	last update
2018	Zhe A. Cheng, Andres Alba-Perez, Cristina Gonzalez-Garcia, Hannah Donnelly, Virginia Llopis-Hernandez, David W. Shields, Laura Ruiz-Cantu, Andrew Reid, James F. C. Windmill, Elena S. Addison, Sandra Corr, William G. Marshall, Matthew J. Dalby and Manuel Salmeron-Sanchez Engineering nanoscale coatings for ultra-low-dose BMP-2-driven regeneration of critical-size bone defects published pages: , ISSN: 2095-6231, DOI:	Nature: Bone Research (In review)	2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPRAYNERGY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPRAYNERGY" are provided by the European Opendata Portal: CORDIS opendata.